On an acquisition spree to enhance derma portfolio Deal to be EPS neutral over the medium term...
Eris Lifesciences is currently trading at Rs. 590.60, up by 6.80 points or 1.16% from its previou...
Indian drugmaker Eris Lifesciences Ltd said on Thursday it had bought nine dermatology brands fro...
Driven by standalone growth (14% to Rs3.5bn) and Oaknet’s contribution (Rs681m), Eris&rsquo...
Niche launches to aid growth over the medium term Promising start for Drolute and Xsulin * ...
In line 4QFY22 at the operational level; geared up for launches in FY23 Specialty segment gets...
The Pharma Brand Master Mix of Chronic portfolio, rising coverage, and better operating levera...
The company reported standalone net profit of Rs 69.35 crore for the quarter ended March 31, 2021...